However, studies targeting the lung microbiome have not been completed.434 Owing to Th17 induction by the lung microbiome, combined with the fact that lung cancer is distinguished by an immune microenvironment rich in Th17 cell responses and IL-17 and other cytokine expression, we speculate that targeting IL-17 in combination with immunotherapy may improve the therapeutic responses of lung cancer patients. This evidence concerns the gene IL17A and lung carcinoma.